Expert Opinion on Emerging Drugs

Papers
(The TQCC of Expert Opinion on Emerging Drugs is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs57
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity51
Bruton’s tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis34
Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials29
Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer27
Emerging drugs for the treatment of diabetic retinopathy21
Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD)20
Emerging synthetic drugs for the treatment of liver cirrhosis16
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer16
Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials15
Emerging drugs for the treatment of neuromyelitis optica13
New drugs under development for COPD13
Behçet’s disease uveitis: is there a need for new emerging drugs?12
Emerging drugs for the treatment of adult MOG-IgG-associated diseases12
Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma12
Emerging therapeutics in Huntington’s disease11
Epilepsy: expert opinion on emerging drugs in phase 2/3 clinical trials11
Emerging therapies for dry eye disease11
Emerging drugs for the treatment of light chain amyloidosis10
Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists10
Designing phase II clinical trials in Friedreich ataxia10
Emerging drugs for treatment of focal segmental glomerulosclerosis10
Emerging drugs for the treatment of epidermolysis bullosa9
Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials9
Clinical trials and novel therapeutics in dermatomyositis9
Emerging topical drugs for the treatment of rosacea9
Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma8
Emerging drugs for the treatment of hidradenitis suppurativa8
Emerging drugs for the treatment of chronic pruritic diseases8
Emerging antiviral therapies and drugs for the treatment of influenza8
Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa7
Emerging immune checkpoint inhibitors for the treatment of head and neck cancers7
Emerging drugs for the treatment of alopecia areata7
Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia7
Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials7
Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials6
Emerging drugs for the treatment of postsurgical pain6
Emerging drugs for the acute treatment of relapses in adult neuromyelitis optica spectrum disorder patients6
Emerging biological therapies for the treatment of age-related macular degeneration6
Cell cycle inhibitors for the treatment of acute myeloid leukemia: a review of phase 2 & 3 clinical trials6
Emerging therapeutics for the management of COVID 196
Emerging drugs for the treatment of myasthenia gravis6
0.022754907608032